Gemcitabine Combined with Gefitinib in Patients with Inoperable or Metastatic Pancreatic Cancer: A Phase II Study of the Hellenic Cooperative Oncology Group with Biomarker Evaluation

REFERENCES

• Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., Thun M. J. Cancer statistics, 2006. CA Cancer J. Clin. 2006; 56: 106–130
   PubMed Web of Science ®Google Scholar
• Sultana A., Smith C. T., Cunningham D., Starling N., Neoptolemos J. P., Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J. Clin. Oncol. 2007; 25: 2607–2615
   PubMed Web of Science ®Google Scholar
• Van Cutsem E., van de Velde H., Karasek P., Oettle H., Vervenne W. L., Szawlowski A., Schoffski P., Post S., Verslypse C., Neumann H., Safran H., Humblet Y., Perez Ruixo J., Ma Y., Von Hoff D. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 2004; 22: 1430–1438
   PubMed Web of Science ®Google Scholar
• Louvet C., Labianca R., Hammel P., Liedo G., Zampino M. G., Andre T., Zaniboni A., Ducreux M., Aitini E., Taieb J., Faroux R., Lepere C., de Gramont A. GERCOR; GISCAD. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J. Clin. Oncol. 2005; 23(15)3509–3516
   PubMed Web of Science ®Google Scholar
• Hochster H. S., Haller D. G., de Gramont A., Berlin J. D., Philip P. A., Moore M. J., Ajani J. A. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer 2006; 107(4)676–685
   PubMed Web of Science ®Google Scholar
• Xie D. R., Liang H. L., Wang Y., Guo S. S., Yang Q. Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone. World. J. Gastroenterol. 2006; 12(43)6973–81
   PubMed Web of Science ®Google Scholar
• Overholser J. P., Prewett M. C., Hooper A. T., Waksal H. W., Hicklin D. J. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 2000; 89(1)74–82
   PubMed Web of Science ®Google Scholar
• Yamanaka Y., Friess H., Kobrin M. S., Buchler M., Beger H. G., Korc M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 1993; 3(3)565–569
   Google Scholar
• Bruns C. J., Solorzano C. C., Harbison M. T., Ozawa S., Tsan R., Fan D., Abbruzzese J., Traxler P., Buchdunger E., Radinsky R., Fidler I. J. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000; 60(11)2926–2935
   PubMed Web of Science ®Google Scholar
• Bruns C. J., Harbison M. T., Davis D. W., Portera C. A., Tsan R., McConkey D. J., Evans D. B., Abbruzzese J. L., Hicklin D. J., Radinsky R. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res. 2000; 6(5)1936–1948
   PubMed Web of Science ®Google Scholar
• Li J., Kleeff J., Giese N., Buchler M. W., Korc M., Friess H. Gefitinib (‘Iressa’, ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. Int. J. Oncol. 2004; 25(1)203–210
   PubMed Web of Science ®Google Scholar
• Therasse P., Arbuck S. G., Eisenhauer E. A., Wanders J., Kaplan R. S., Rubinstein L., Verweij J., Van Glabbeke M., van Oosterom A. T., Christian M. C., Gwyther S. G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000; 92(3)205–216
   PubMed Web of Science ®Google Scholar
• Ajani J. A., Welch S. R., Raber M. N., Fields W. S., Krakoff I. H. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest. 1990; 8(2)147–59
   PubMed Web of Science ®Google Scholar
• Pallares J., Bussaglia E., Martinez-Guitarte J. L., Dolcet X., Llobet. D., Rue M., Sanchez-Verde L., Palacios J., Prat J., Matias-Guiu X. Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Modern. Pathol. 2005; 18: 719–727
   PubMed Web of Science ®Google Scholar
• Italiano A., Saint-Paul M. C., Caroli-Bosc F. X., Francois E., Bourgeon A., Benchimol D., Gugenheim J., Michiels J. F. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. Ann. Oncol. 2005; 16: 1503–1507
   PubMed Web of Science ®Google Scholar
• Choe G., Horvath S., Cloughesy T. F., Crosby K., Seligson D., Palotie A., Inge L., Smith B. L., Sawyers C. L., Mischel. P. S. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 2003; 63: 2742–2746
   PubMed Web of Science ®Google Scholar
• Perren A., Weng L. P., Boag A. H., et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am. J. Pathol. 1999; 155: 1253–1260
   PubMed Web of Science ®Google Scholar
• Fountzilas G., Karkavelas G., Kalogera-Fountzila A., Karina M., Ignatiadis M., Koukoulis G., Plataniotis G., Misailidou D., Bobos M., Pectasides D., Razis E., Karavelis A., Selviaridis P. Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation. Anticancer Res. 2006; 26: 4675–4686
   PubMed Web of Science ®Google Scholar
• Sunpaweravong P., Sunpaweravong S., Puttawibul P., Mitarnun W., Zeng C., Baron A. E., Franklin W., Said S., Varella-Garcia M. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 2005; 131: 111–119
   PubMed Web of Science ®Google Scholar
• Murray S., Timotheadou E., Linardou H., Vrettou A. V., Kostopoulos I., Skrickova J., Papakostantinou C., Christodoulou C., Pectasides D., Samantas E., Papakostas P., Skarlos D. V., Kosmidis P., Fountzilas G. Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients. Lung Cancer 2006; 52: 225–233
   PubMed Web of Science ®Google Scholar
• Travis W. D., Colby T. V., Corrin B., Shimosato Y., Brambilla E. Histological typing of lung and pleural tumors 3rd edition. Springer Verlag, Berlin 1999
   Google Scholar
• Pao W., Wang T. Y., Riely G. J., Miller V. A., Pan Q., Ladanyi M., Zakowski M. F., Heelan R. T., Kris M. G., Varmus H. E. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS. Med. 2005; 2: 57–61
   Web of Science ®Google Scholar
• Moore M. J., Goldstein D., Hamm J., Figer A., Hecht J. R., Gallinger S., Au H. J., Murawa P., Walde D., Wolff R. A., Campos D., Lim R., Ding K., Clark G., Voskoglou-Nomikos T., Ptasynski M., Parulekar W. National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007; 25: 1960–1966
   PubMed Web of Science ®Google Scholar
• Shadad F., Phase I I. study of gefitinib and docetaxel as salvage therapy in patients with advanced pancreatic adenocarcinoma. J. Clin. Oncol. 2006; 24((Suppl 18)), (Abstr 4120)
   Web of Science ®Google Scholar
• Cascinu S., Berardi R., Siena S., La bianca R., Falcone A., Aitini E., Barni S., Di Costanzo F., Frontini L., Tonini G., Zaniboni A. The impact of cetuximab on the gemcitabine/cisplatin combination in first-line treatment of EGFR-positive advanced pancreatic cancer (APC): A randomized phase II trial of GISCAD. J. Clin. Oncol. 2007; 25((Suppl 18)), (Abstr 4544)
   Google Scholar
• Abou-Alfa G. K., Letourneau R., Harker G., Modiano M., Hurwitz H., Tchekmedyian N. S., Feit K., Ackerman J., De Jager R. L., Eckhardt S. G., O'Reilly E. M. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J. Clin. Oncol. 2006; 24(27)4441–4447
   PubMed Web of Science ®Google Scholar
• Perez-Soler R., Delord J. P., Halpern A., Kelly K., Krueger J., Sureda B. M., von Pawel J., Temel J., Siena S., Soulieres D., Saltz L., Leyden J. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist. 2005; 10(5)345–356, Review
   PubMed Web of Science ®Google Scholar
• Lynch T. J., Jr, Kim E. S., Eaby B., Garey J., West D. P., Lacouture M. E. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007; 12: 610–621
   PubMed Web of Science ®Google Scholar
• El-Rayes B. F., Ali S., Ali I. F., Philip P. A., Abbruzzese J., Sarkar F. H. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. Cancer Res. 2006; 66: 10553–10559
   PubMed Web of Science ®Google Scholar
• Safran H., Steinhoff M., Mangray S., Rathore R., King T. C., Chai L., Berzein K., Moore T., Iannitti D., Reiss P., Pasquariello T., Akerman P., Quirk D., Mass R., Goldstein L., Tantravahi U. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am. J. Clin. Oncol. 2001; 24(5)496–499
   PubMed Web of Science ®Google Scholar
• Fernandez M., Eng C. The expanding role of PTEN in neoplasia: a molecule for all seasons? Commentary. Clin. Cancer Res. 2002; 8(6)1695–1698
   PubMed Web of Science ®Google Scholar
• Ohgaki H., Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol. 2007; 170: 1445–1453
   PubMed Web of Science ®Google Scholar
• Hayes M. P., Wang H., Espinal-Witter R., Douglas W., Solomon G. J., Baker S. J., Ellenson L. H. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin. Cancer Res. 2006; 12: 5932–5935
   PubMed Web of Science ®Google Scholar
• Asano T., Yao Y., Zhu J., Li D., Abbruzzese J. L., Reddy S. A.G., The P I. 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kB and c-Myc in pancreatic cancer cells. Oncogene. 2004; 23: 8571–8580
   PubMed Web of Science ®Google Scholar
• She Q. B., Solit D., Basso A., Moasser M. M. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clin. Cancer Res. 2003; 9: 4340–4346
   PubMed Web of Science ®Google Scholar
• Haas-Kogan D. A., Prados M. D., Tihan T., Eberhard D. A., Jelluma N., Arvold N. D., Baumber R., Lamborn K. R., Kapadia A., Malec M., Berger M. S., Stokoe D. J. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. Natl. Cancer Inst. 2005; 97(12)880–887
   Google Scholar
• Yano S., Matsuyama H., Hirata H., Inoue R., Matsumoto H., Ohmi C., Miura K., Shirai M., Iizuka N., Naito K. Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer. Oncol. Rep. 2006; 15(6)1453–1460
   PubMed Web of Science ®Google Scholar
• Han S. W., Kim T. Y., Jeon Y. K., Hwang P. G., Im S. A., Lee K. H., Kim J. H., Kim D. W., Heo D. S., Kim N. K., Chung D. H., Bang Y. J. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin. Cancer Res. 2006; 12: 2538–2544
   PubMed Web of Science ®Google Scholar
• Kwak E. L., Jankowski J., Thayer S. P., Lauwers G. Y., Brannigan B. W., Harris P. L., Okimoto R. A., Haserlat S. M., Driscoll D. R., Ferry D., Muir B., Settleman J., Fuchs C. S., Kulke M. H., Ryan D. P., Clark J. W., Sgroi D. C., Haber D. A., Bell D. W. Epidermal growth factor receptor kinase domain mutation in esophageal and pancreatic adenocarcinomas. Clin. Cancer Res. 2006; 12: 4283–4287
   PubMed Web of Science ®Google Scholar
• Lee J., Jang K. T., Ki C. S., Lim T., Park Y. S., Lim H. Y., Choi D. W., Kang W. K., Park K., Park J. O. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 2007; 109: 1561–1569
   PubMed Web of Science ®Google Scholar
• Paez J. G., Janne P. A., Lee J. C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F. J., Lindeman N., Boggon T. J., Naoki K., Sasaki H., Fujii Y., Eck M. J., Sellers W. R., Johnson B. E., Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497–1500
   PubMed Web of Science ®Google Scholar